Four posters describing the Company’s platform to be presented, including a third-party clinical study poster of the Stool Bacterial Pathogens Panel
Salt Lake City, June 1, 2017 – Great Basin Scientific, Inc. (OTCQB: GBSN), a molecular diagnostics company, announced today that it will present three posters describing the reliability and effectiveness of its diagnostic platform to attendees of ASM Microbe 2017, which is being held June 1-5, 2017 in New Orleans. Additionally, Dr. Paul Granato from the Laboratory Alliance of Central New York will present a poster summarizing the results of a multi-site independent clinical study evaluating the Company’s Stool Bacterial Pathogens Panel, which is awaiting 510(k) clearance from the U.S. Food and Drug Administration (FDA). In the independent study, the Company’s Stool Bacterial Pathogens Panel is shown to process results in approximately two hours with superior detection rates of over 97% compared to 51% for conventional culture and EIA methods.
“We are very pleased to continue to show a growing body of data demonstrating how our cost-effective, sample-to-result platform can support our customers’ needs and, we believe, provide better patient outcomes,” said Ryan Ashton, co-founder and chief executive officer of Great Basin Scientific. “We are particularly proud of the results we have seen from our highly-anticipated Stool Bacterial Pathogens Panel, which we believe addresses the testing and reimbursement challenges affecting our healthcare system. Data shows our panel produces highly accurate and fast diagnosis in a multiplex assay that detects the top 90-95 percent of foodborne infections; Salmonella species, Shigella species, Shiga Toxin-producing E. coli (stx1, stx 2, O157 serotype-specific genes), and Campylobacter species (C. jejuni and C. coli).”
Great Basin will present the following posters during this year’s ASM Microbe event:
- Poster #468, Friday, June 2, 2017
Rapid Detection and Differentiation of the Recently Emerged Multidrug Resistant Candida auris Species and Other Major Clinically Relevant Candida Species Simultaneously and Accurately from Blood Cultures Using a Novel Amplification Process – will be presented in a poster talk by Wanyuan Ao of Great Basin Scientific.
This presentation describes application of Great Basin’s patented AMPED method to the highly specific detection of eight Candida species, including the recently emerging and broadly resistant Candida auris. The described test is highly specific to the individual species and with limits of detection of less than 100 CFU directly from positive blood cultures without the need for target amplification approaches such as PCR.
- Poster #473, Friday, June 2, 2017
The Staph ID/R Blood Culture Panel: An FDA Cleared Rapid Detection Method for Staphylococcus and the mecA Gene Direct from Positive Blood Culture; by Jason M. Foulks, Jamie Purcell, Krystle Minear, Annah Frisch, Camrin Rivera, Wanyuan Ao, Maylene Corpuz, Adrianne Clifford, Lindsey Enright, Denton Munns, James Miess, Brandon Cook, Wes Lindsey, Robert Jenison; Great Basin Scientific, Inc., Salt Lake City, UT.
This presentation summarizes the analytical performance data supporting FDA clearance of the Staph ID/R Blood Culture panel. The test was demonstrated to have very broad and sensitive reactivity within the genus and can detect mecA resistance in all Staphylococcus including S. aureus and S. lugdunensis at the species level.
- Poster #469, Saturday, June 3, 2017
Great Basin Stool Bacterial Pathogens Panel for Rapid Identification of Salmonella, Shigella, Shiga Toxin-Producing E. coli, and Campylobacter in Symptomatic Patients; by Nicole J. Davis, Wanyuan Ao, Emily Wirick, Stefanie Marxreiter, Brandon Cook, Justin Crandall, Megan Warner, Wes Lindsey, and Rob Jenison; Great Basin Scientific, Inc., Salt Lake City, UT.
This presentation summarizes the analytical performance data supporting the clinical evaluation of the Stool Bacterial Pathogens Panel, currently under review by the FDA.
A clinical study of the Company’s Stool Bacterial Pathogens Panel done by third-party researchers will also be presented:
- Poster #1390, Saturday, June 3, 2017
Comparative Evaluation of a PCR Amplification and Array Detection Stool Bacterial Pathogens Panel with Conventional Methods for Detecting Common Bacterial Enteric Pathogens – will be presented by Dr. Paul Granato of the Laboratory Alliance of Central NY, Syracuse, NY
Posters will be available after ASM Microbe 2017 on the Great Basin website at www.gbscience.flywheelsites.com, or on ASM’s website, http://www.asmmicrobe.org/images//AbstractsPull_6-1.pdf.
The American Society for Microbiology (ASM) is the largest single life science society, composed of over 47,000 scientists and health professionals. ASM’s mission is to promote and advance the microbial sciences. ASM advances the microbial sciences through conferences, publications, certifications, and educational opportunities. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry, and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to diverse audiences. For more information about ASM, please visit http://www.asm.org/.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the Company’s website at www.gbscience.flywheelsites.com.
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect future operating results and financial position, including but not limited to statements regarding the Company’s ability to license its technology, the ability to add revenue from such license arrangements and its ability to expand the use of the amplification suppressor technology in future tests and panels. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) limited operating history and history of losses; (ii) ability to develop and commercialize new products and the timing of commercialization; (iii) ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 and in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2017. These forward-looking statements speak only as of the date hereof, and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.